Retrospective Independent Safety Review of Closed Irrisept Study

Adverse Events Clinical Trial

Official title:

An Independent Review of Safety Data From a Closed Clinical Study Using Irrisept (Protocol IRR-CT-901-2013-01)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05359666
• Other study ID #: CLP-01
• Status: Completed
• Phase: N/A
• Start date: March 31, 2020
• Est. completion date: November 29, 2021

Study information

• Verified date: July 2023
• Source: Irrimax Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of CLP-01 was to complete the safety endpoint of the closed trial and ensure that all safety data generated by IRR-CT-901-2013-01 was accounted for and accurately identified, verified, and independently adjudicated. CLP-01 does not include an evaluation of the efficacy or exploratory endpoints from IRR-CT-901-2013-01. CLP-01 did not enroll new subjects and relied solely on data collected in the subject source and medical records in IRR-CT-901-2013-01. CLP-01 was conducted between March 2020 and November 2021.

Description:

Between 2013 and 2016, Irrimax Corporation sponsored a prospective clinical study (IRR-CT-901-2013-01; NCT02255487) in the United States under IRB approval. IRR-CT-901-2013-01 defined primary and secondary efficacy, exploratory, and safety endpoints. The safety endpoint from IRR-CT-901-2013-01 was a clinical review and analysis of Adverse Events (AEs). However, IRR-CT-901-2013-01 was terminated early after the Interim Analysis primarily because of issues with the accuracy and completeness of the data collected for IRR-CT-901-2013-01, the lack of SoC standardization, and challenges assessing study endpoints arising out of the complexity of the trauma and co-morbidities of the subjects enrolled. The sole purpose of CLP-01 was to complete the safety endpoint for IRR-CT-901-2013-01.

CLP-01 reviewed all AEs recorded in IRR-CT-901-2013-01 and identified additional AEs in the subject source and medical records. All AEs were assessed for severity and causality and were reviewed by the individual Principal Investigators (PIs) at each site and the CLP-01 Medical Monitor (MM).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 592
• Est. completion date: November 29, 2021
• Est. primary completion date: November 29, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Previously consented subjects from the closed study

• Subjects randomized to use Irrisept or SoC in the closed study

• Subjects who had a procedure in the hospital

• Subjects who used irrigation during the hospital procedure

• Subjects who had data that could be monitored and verified

Exclusion Criteria:

-Subjects who did not meet all inclusion criteria

The total number of subjects in this population - the mITT population - was 592.

Related Conditions & MeSH terms

• Adverse Events

Intervention

Device:
• Irrisept
Irrisept® is a manual, self-contained irrigation device designed for wound cleansing and irrigation. The solution is 0.05% Chlorhexidine Gluconate (CHG) in sterile water for irrigation, USP (99.95%). Irrisept contents include the solution, a 450 mL bottle, and the Irriprobe applicator. Irrisept is a manual, self-contained irrigation device that can produce 7-8 psi of pressure for effective wound cleansing and irrigation. The user squeezes the bottle to create streams of solution and directs the fluid from the applicator onto a wound. The mechanical action of the streams of fluid being applied over a wound removes particulates and debris. Subjects randomized to Irrisept on study protocol IRR-CT-901-2013-01 used the device, per the provided Instructions for Use. Those randomized to SoC received routine care, per the discretion of the investigator, and in accordance with the institution's guidelines.
• Standard of Care
Subjects randomized to SoC on study protocol IRR-CT-901-2013-01 used any SoC type, per the investigator's discretion. SoC types were not standardized. Sites recorded SoC information as free text. The following were recorded as SoC types: Saline (recorded as "normal", "warm" and/or "sterile" saline or saline solution); Sodium Chloride (recorded as "sodium chloride (NACL)" or "NACL 0.9%"); "SoC"; Irrisept (recorded as "normal saline & Irrisept" and "Irrisept"); Chloraprep; "Gentamicin & saline"; unknown; and none.

Locations

Country	Name	City	State
United States	University of Maryland	Baltimore	Maryland
United States	University of Cincinnati Division of Trauma/Critical Care Department of Surgery	Cincinnati	Ohio
United States	MetroHealth Medical Center	Cleveland	Ohio
United States	University of Texas Southwestern (UTSW) Medical Center	Dallas	Texas
United States	Denver Health Medical Center	Denver	Colorado
United States	University of Texas Health Science Center (UTHSC) at Houston Center for Translational Injury Research	Houston	Texas
United States	University of Iowa Department of Surgery - 1504 JCP	Iowa City	Iowa
United States	University of Kentucky Department of Surgery	Lexington	Kentucky
United States	Los Angeles County & USC Medical Center	Los Angeles	California
United States	University of Tennessee Health Science Center	Memphis	Tennessee
United States	Medical College of Wisconsin Division of Trauma & Acute Care Surgery	Milwaukee	Wisconsin
United States	St. Louis University Department of Surgery	Saint Louis	Missouri
United States	The University of Texas Health Center at San Antonio Division of Trauma and Emergency Surgery	San Antonio	Texas
United States	University of Washington Harborview Medical Center Department of Surgery	Seattle	Washington
United States	Baystate Medical Center Surgery Research, S3613	Springfield	Massachusetts
United States	Tampa General Hospital University of South Florida (USF) College of Medicine	Tampa	Florida
United States	University of Arizona Department of Surgery	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Irrimax Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All Adverse Events	The primary endpoint was identification of all adverse events from subjects that participated in the closed study (Protocol #IRR-CT-901-2013-01; NCT #02255487).	up to 30 +/- 3 days
Secondary	Subjects With Device-Related Adverse Events	The secondary endpoint was identification of the number subjects with device-related adverse events from those that participated in the closed study (Protocol #IRR-CT-901-2013-01; NCT #02255487).	up to 30 +/- 3 days
Secondary	Number of Device-Related Adverse Events	Another secondary endpoint was identification of the overall number device-related adverse events from subjects that participated in the closed study (Protocol #IRR-CT-901-2013-01; NCT #02255487).	up to 30 +/- 3 days
Secondary	Number of Device Deficiencies	For the Irrisept group only, any device deficiencies identified in the medical records and/or source documents (during the closed study when the study device was used, even if the deficiency was not associated with an AE), was recorded.	up to 30 +/- 3 days